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Abstract
It is often claimed that genes affecting health in old age, such as cardiovascular and Alzheimer diseases, are beyond the
reach of natural selection. We show in a simulation study based on known genetic (apolipoprotein E) and non-genetic risk
factors (gender, diet, smoking, alcohol, exercise) that, because there is a statistical distribution of ages at which these genes
exert their influence on morbidity and mortality, the effects of selection are in fact non-negligible. A gradual increase with
each generation of the e2 and e3 alleles of the gene at the expense of the e4 allele was predicted from the model. The e2
allele frequency was found to increase slightly more rapidly than that for e3, although there was no statistically significant
difference between the two. Our result may explain the recent evolutionary history of the epsilon 2, 3 and 4 alleles of the
apolipoprotein E gene and has wider relevance for genes affecting human longevity.
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Introduction
Evidence points towards the existence of a strong heritable
component of human longevity [1,2]. Around a quarter to a third
of the variability of lifespan can be attributed to the action of genes
[3,4,5,6,7]. One of the best examples of a gene affecting survival in
old age is the apolipoprotein E gene APOE. Situated on human
chromosome 19 at locus 19q13.32 (http://genome.ucsc.edu/,
assembly (hg18)), the APOE gene is 3.6 kb long containing four
exons and coding for a 317 amino-acid polypeptide that after
cleavage gives rise to a 299 amino-acid long mature protein [8,9].
Apolipoprotein E (APO E) is a member of a diverse family of
carrier proteins specializing in lipoprotein particle formation,
secretion, transport, binding and metabolism [10]. APO E is
synthesized in many different regions of the body such as the liver,
brain (primarily astrocytes), skin, macrophages and steroidogenic
organs [11].
APO E has three major and more than thirty minor isoforms,
the latter being mostly linked with disease. The three common
alleles are epsilon (e) 2, 3 and 4 producing three homozygous (e2/
e2, e3/e3 and e4/e4) and three heterozygous (e2/e3, e3/e4 and e2/
e4) genotypes [12]. The difference between the alleles lies at two
amino acid residues 112 and 158; with the most common allele e3
having cysteine and arginine at these residues, respectively, while
e2 has cysteine and e4 arginine at both locations [9]. Carriers of
different alleles show differences in the incidence of coronary
artery disease (CAD), peripheral atherosclerosis, Alzheimer
disease, possibly stroke and even ability to recover from trauma
[11,13,14,15,16]. The underlying mechanism for the action of the
gene involves an inter-domain interaction between the amino- and
carboxyl- terminals of the protein, producing isoform-specific
lipoprotein preferences such that E2 and E3 protein isoforms bind
preferentially to HDL (the ‘‘good’’ cholesterol), while the E4
isoform shows a preference for VLDL [17]. The APO E2 isoform
is defective in binding the LDL receptor, although it retains its
ability to interact with LDL-receptor-related protein and other
related receptors [11]. A small number of e2 homozygotes suffer
from a condition known as type III hyperlipoproteinemia,
characterized by accumulation of cholesterol-rich remnant
lipoproteins due to incomplete catabolism of chylomicrons and
VLDL, leading to premature atherosclerosis. The fact that
although 90% of the patients are e2 homozygotes, but only 5%
of the e2 homozygotes suffer from the condition, suggests that
further factors are required for the phenotypic expression of the
condition [18,19].
Generally in Caucasian populations survival to advanced age is
more likely for carriers of the e2 allele than for e3 homozygotes
and less likely for carriers of the e4 allele [20,21,22,23,24]. The e4
allele is strongly associated with increased risk of coronary heart
disease (CHD) [14,25,26,27,28], while for the e2 allele there is
some, though weaker, evidence for a protective effect [29,30]. The
APOE polymorphism, has also been implicated in Alzheimer’s
disease (AD), which is the commonest form of senile dementia
[31,32]. With the e4 allele shown, in a number of studies, to be
associated with both familial and sporadic forms of the disease,
causing higher incidence and earlier age of onset, and affecting its
pathology and rate of progression [33,34]. Normal age-associated
cognitive decline, and mild cognitive impairment and the risk of its
conversion to AD have also been repeatedly associated with the
presence of the e4 allele [35].
One of the major ideas in the evolutionary theory of ageing [36]
is the suggestion that, because the force of natural selection
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declines with age, alleles with deleterious effects seen only at older
ages can reach higher frequencies than those that have their effects
earlier in life [37]. Therefore, if a gene exerts an effect only after
the end of the reproductive phase of the lifespan it has been
thought unlikely that it could have been subject to significant
direct selection pressure, and this would seem to be the case for
genes affecting late-life diseases such as AD and CHD [38,39].
Nevertheless, the worldwide abundance of e3, as compared to e4
which, from studies in non-human primates appears to be the
ancestral allele [40,41], suggests that selection has acted upon
these alleles. Here, we use a simulation approach based on the
known risk factors for cardiovascular disease (CVD) to examine
the hypothesis that the evolution of the APOE gene was, and still is,
driven by its role in lipid metabolism and its subsequent effects on
health.
Methods
Risk factors
The selection of modifiable risk factors to include in the
simulation was based on current knowledge of lifestyle parameters
affecting cardiovascular disease (CVD) while keeping in mind the
need for independence between the risk factors, simplicity and
availability of data. There are two categories of risk factors
associated with CVD: non-modifiable risk factors, such as APOE
genotype, and gender, and modifiable risk factors, such as smoking,
unhealthy diet, lack of physical activity and high alcohol
consumption [42]. For the non-modifiable risk factors, the
estimated genotype relative risk used was from Gerdes et al [29],
while the gender difference in CVD was based on the results of
Panagiotakos et al [43]. To quantify the effect of diet, we used the
five clusters described by Millen et al [44] in the Framingham
study (Heart Healthy, Light Eating, Wine and Moderate Eating,
High Fat, and Empty Calorie) [44,45]. For alcohol, smoking and
exercise, we used the risk estimates from Stampfer et al [46].
Genotype-environment interaction
A number of studies found evidence of interaction between the
APOE genotype and each of the modifiable risk factors considered
in the model (diet, [9,47,48,49]; alcohol [50,51,52]; smoking
[53,54]; and exercise [55]), although the results are sometimes
conflicting. Importantly, their precise interaction in quantitative
terms remains unknown and will ultimately require a series of
studies in large populations before the levels of genotype-
environment interactions can be estimated with adequate
precision.
Here we use the association of APOE and diet to illustrate the
principles used to account for the unknown interaction terms. Our
first assumption was that, except APOE, the risk factors considered
were independent of each other. Then we assumed that the
relative risk weighted average of the risk factor, for all APOE
alleles, was approximately 1, i.e. equal to the reference e3e3
genotype. According to the Odds Ratios (OR) given in Gerdes et
al [29] the weighted average is (e2 OR6e2 freq+e3e3 OR6e3e3
freq+e4 OR6e4 freq; 0.8860.11+160.71+1.160.18= 1.005).
Treating both variables as ordinal, we can fit a model between
the two factors; in this case a quadratic model gave the best fit to
the data. Assuming that all genotypes will have the same OR at
some hypothetical level of the modifiable risk factor and
considering that the overall OR between the APOE genotypes is
dependent on their weighted difference for each category of diet
intake, making use of the correspondence of the overall weighted
mean to the e3e3 genotype, we can work out the beta coefficient
for each of the other APOE genotypes. Using similar techniques we
computed the interaction components for all of the remaining risk
factors.
Calculating risk
Despite OR overestimating risk for common diseases such as
CVD [56,57], many researchers do use it to report their results.
To approximate the relative risk (RR) from the OR we used the
very popular methodology of Zhang and Yu [58] as being both the
simplest and the one that requires the least information for the
dataset used. Despite the method’s slight inaccuracy in calculating
confidence intervals and its inability to account for confounding
factors, its balance between simplicity and precision make it an
especially useful tool [56,57].
The total risk of an individual could be calculated as the product
of the gender relative risk and all four modifiable risk factors,
corresponding to the individual’s specific genotype. We used a
proportional hazard model to estimate the mortality schedule of
an individual having relative risk R at a specific age x. According to
this, if m1(x) is the hazard of death of genotype 1 at age x, and m2(x)
is the hazard of death of a genotype 2 at the same age x, then
m1(x) =R6m2(x), where R expresses the relative risk [29].
Simulating evolutionary change
Our simulated populations comprised individuals with random-
ly assigned genotype, gender and lifestyle parameters from a
typical western population. The random draws were done using
the MT19937 pseudorandom generator, a variation of the
‘‘Mersenne Twister’’ generator (GSL Reference Manual). Equal
number of males and females were generated and subsequently
paired as couples randomly. These couples reproduced to age 50
or until either of the individuals died. The reproductive schedule
was the same as what is found in contemporary western
populations, with a series of binomials distributions describing
the chance of a successful birth for each year of life and the
probability decreasing with increasing adult age. The age of death
was obtained from a Gumbell distribution based on demographic
tables for the UK (Office for National Statistics) and a relative risk
corresponding to the life style parameters of the simulated
individual. Each offspring was given a genotype based on the
genotypes of its parents, and all the produced genotypes were
pooled into a matrix constituting the initial conditions for the next
generation. The process was repeated as many times as the
number of generations required. The entire simulation was written
in C++ and performed using a 16 CPUs Unix cluster.
Statistical analysis of the results
The Mathematica 4.1 package was used to collect analyse the
output of the simulations. To minimize random variation of the
results, a set of 60 runs, each comprising 200,000 individuals
followed for 50 generations, was used. We summarized the data
calculating the mean and standard deviation of all 60 runs for each
generation and each allele. A random walk in one dimension was
used to obtain the average change per generation, assuming that
the change of the allele frequencies was linear and could be
described by a simple equation. As long as the alleles do not have a
pleiotropic effect balancing the selection for or against them, their
frequencies in a stable environment were expected to increase until
they were fixed or became extinct in the population. A simple
equation describing the change could be written as:
at~at{1zdz
X
t ð1Þ
where at is the frequency at time or generation t, at-1 is frequency
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in the previous generation, d is the change between two
consecutive points in the series and St is random noise normally
distributed. In order to calculate d we estimated a yjt such that:
yj t~aj tz1{aj t
with simulation run j~1, . . . ::,60
and generation number i~1, . . . ::,49
returning a matrix of 49660 elements. From this, the mean d and
its 95% confidence intervals (95% CIs) could be calculated. If the
95% CIs are positive then there is evidence for a significant
increase of the allele frequency with each generation, while if
negative the allele goes towards extinction. In the case that 0 is
included within the confidence interval, the change of frequency
cannot be considered statistically significant and selection is either
extremely weak or due to chance. The data were also transferred
into Minitab statistical software to test for statistical significance
between and within different variants of the simulation.
Results
Starting with APOE genotype frequencies of 1.7% e2e2, 11.6%
e2e3, 55.8% e3e3, 1.9% e2e4, 25.1% e3e4, and 3.9% e4e4 and
modifiable risk factor distributions as reported in Millen et al [44]
and Stampfer et al [46], and assuming the same population
distribution between males and females, the mean life expectancy
at birth for the simulated individual was 75.7 years with females
having 5.4 years longer expected lifespan than males. The
differences in mortality between APOE genotype classes as fitted
in the model can be seen in Figure 1, with e2 carriers living 1 (OR
0.9) year more, and e4 carriers living 1.2 (OR 1.13) years less, than
the e3e3 reference genotype. In figure 2, the curves obtained when
the interaction between genotype and diet was considered can be
seen, while table 1 has the calculated relative risk for each
combination of diet and APOE genotype. For the force of natural
selection on the APOE gene, we observed a positive selection for
the e2 (mean frequency change per generation 3.35261024, 95%
CI 2.66161024 to 4.04361024) and e3 (mean 2.78561024 95%
CI 1.80961024 to 3.76161024) alleles against e4 (mean
26.13761024 95% CI 26.94661024 to 25.32761024), with
the e2 frequency increasing slightly more rapidly than that for e3,
although there was no significant difference between them
(Figure 3).
Considering that only a fraction of the population will suffer
from APOE related diseases, a variant of the model with 30% of
the total mortality attributed to CVD was also tested. Again, the
results pointed to a positive selection of the e2 and e3 alleles (e2
mean 0.84661024, 95% CI 0.49761024 to 1.19561024; e3 mean
0.84661024, 95% CI 0.31661024 to 1.37761024) and a negative
selection for the e4 allele (mean 21.69261024, 95% CI
22.14061024 to 21.24461024) which, as expected, was
approximately one third of the change observed previously.
We performed a number of simulation runs with a variety of
different starting conditions both to test the sensitivity of the model
and analyse the likely changes under different lifestyle choices. The
description of all the simulation variants used with their mean life
expectancy at birth can be seen in table 2. The changes in the
distribution of the modifiable risk factors explored, except the
eradication of smoking, were relatively modest and considered
possible to occur, if not already present in certain subgroups of
western populations. It is important to note the unexpected
decrease in mean lifespan when heavy alcohol consumption is
lowered and the slight increase in longevity when non- and very
light drinkers decrease. This effect is due to the U-shaped
relationship between alcohol consumption and health and the re-
arrangement of the population distribution across the categories of
risk.
The estimates for the mean frequency change for each APOE
allele per generation, under all the different models considered
assuming at the same time that only 30% of the population is
affected by any APOE related diseases, are presented in table 3. As
Figure 1. Differences in the distribution of mortality for the three APOE genotype classes. These are estimated using a proportional
hazard model as described in the methods. The e2 carriers have an OR of 0.9 and survive a year more than the e3e3 carriers. In contrast, e4 carriers
have a decreased lifespan of 1.2 years due to an OR of 1.13 compared to the reference genotype.
doi:10.1371/journal.pone.0010022.g001
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can be seen in the table, the selection against the e4 allele and the
increase in the frequency of the e3 and e2 alleles are robust and
remained significant under all the different versions of the
simulation. A notable exception was the loss of significance for
the increase of the e3 frequency when the effect of smoking is
removed from the population (mean 0.25961024, 95% CI
20.05761024 to 0.57461024). The extreme change of removing
all smokers in the population, while in the same time leaving the
percentage of CVD associated mortality at 30%, reaches the
statistical power limits of our current simulation to observe
significance for the selection of the e3 allele in a population of
20,000. For such extreme cases, a corresponding change should
also be made to the mortality schedule and the fraction of the
population affected by that change.
Discussion
We have shown that under certain environmental conditions,
such as those often found in Western populations, the APOE gene
is likely to be under the action of natural selection. According to
the results obtained, the e2 and e3 alleles are increasing with each
successive generation at the expense of the e4 allele, which is
slowly being removed from the population. The selection against
the e4 allele was found to be robust, despite changes to the initial
conditions of the simulation. We failed to find any significant
difference between the increase in frequency of the e2 and e3
alleles, denoting their very similar effects on survival. This accords
with meta-analysis studies which have found it difficult to identify
any statistically significant risk differences between the carriers of
e2 allele and the reference e3e3 genotype, unless a large number of
cases is available, mainly due to the low frequency of e2 in the
populations considered [15].
Despite the difficulty in observing and measuring the force of
natural selection as revealed by change of allele frequencies in
specific polymorphisms, especially in humans, alternative methods
are available to obtain evidence for its action indirectly. APOE
seems to be one of the least variable human genes studied, despite
the average neutral mutation rate [59]. Comparing the chimpan-
zee and human APOE genes, revealed that e4 is probably the
ancestral allele [59]. Indeed, most great apes carry only the e4
allele, although a change of arginine to threonine at position 61
gives this isoform an affinity similar to the human e3 [40,60,61]. It
is unclear when the human e4 allele arose, but a comparison
between coding changes in orthologous genes in five species
(Mouse, Rat, Dog, Chimpanzee and Human) showed positive
selection for APOE along the hominid lineage [62]. Using the
haplotypes defining the three genotypes in a coalescent model,
Fullerton et al [59] proposed that e3 diverged from the e4
haplotype around 200,000 years ago and that e3 is showing
evidence of increasing in frequency, relative to e4. Assuming a
constant selective pressure and a generation time of ,20 years,
given an e3 frequency of around 0.75, a very simple calculation
shows that the required increase of e3 per generation is 7.561025,
close to the order of magnitude predicted from the simulation for
the current change of the allele frequency. Using a similar
argument, we can further propose that since e2 and e3 alleles seem
to be under a similar pressure from natural selection in our
simulation and e2 has a lower frequency in human populations, e2
arose later than e3. Again, analysis of APOE haplotypes using a
reduced median network revealed that e2 was derived from the e3
allele within the last 80,000 years [59].
Assuming a simple and uniform selection pressure on APOE is
rather over simplistic. Current theories suggest a two step
evolution of the locus, one to explain the early evolution of the
Figure 2. Inferred interaction between APOE genotype and diet. Diet categories are considered on an integer scale from 1 to 5 with Heart
Healthy, Light Eating, Wine and Moderate Eating, High Fat, and Empty Calorie clusters [44,45]. We assumed that for a hypothetical diet category 0
there is no distinction in risk between the genotypes.
doi:10.1371/journal.pone.0010022.g002
Table 1. Calculated relative risk for each combination of diet
category as described by Miller et al (2001) and APOE
genotype.
APOE genotype 22 23 33 34 44
Hypothetical diet 0 0.944 0.944 0.944 0.944 0.944
Heart Healthy 0.979 0.981 0.984 0.987 0.990
Light Eating 1.083 1.093 1.104 1.116 1.129
Wine and Moderate Eating 1.256 1.280 1.304 1.332 1.360
High Fat 1.499 1.541 1.584 1.633 1.683
Empty Calorie 1.811 1.877 1.944 2.020 2.099
doi:10.1371/journal.pone.0010022.t001
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human alleles and a second step to account for their current global
frequencies. Despite the very sparse evidence for both, and their
rather conflicting views for the selection pressures applied, the
proposed mechanisms are interesting and reveal the importance of
APOE in human evolution. Finch and Stanford [63] and Finch and
Sapolsky [60] suggested that APOE is a ‘‘meat adaptive’’ gene that
permitted increased consumption of animal tissue during hominid
evolution while conferring resistance to the associated risks such as
hypercholesterolemia and infections, allowing for the extension of
human lifespan. In their view, this increase in meat eating
provided humans with a solution to seasonal deficits of
micronutrients. In addition, relatively safe consumption of nutrient
dense meat is believed to have lead to an increase of body size,
without restricting activity, and conferred the extra energy
required for the cerebral expansion of early humans [64,65]. On
the other hand, the frequencies of the three common alleles vary
widely between populations of different ethnic backgrounds. In
general e3 is globally the most common allele, with Africans
having the lowest allele frequency (#70%) compared to Cauca-
sians (70–80%) and East Asians ($80%) [66]. In Europe, and
between populations of Caucasian descent, there is a north-to-
south gradient of decreasing e4 frequency opposite to the spread of
agriculture [67,68]. This has led Corbo and Scacchi [69] to
suggest that APOE is a thrifty gene, with the e4 allele being
advantageous under seasonal periods of starvation, due to its
elevating effect of cholesterol which would otherwise be too low,
but detrimental in areas where carbohydrates were readily
available, such as those with a long history of agriculture, thus
the north-to-south pattern observed in Europe. Doubts have been
raised about the lack of seasonal starvation in food producing
societies [70], while the hypothesised selection for e4 in pre-
agricultural times is opposite to the one suggested by Finch and
Sapolsky [60,63].
Although it is clear that variation in the APOE locus has been,
and probably still is, under the control of selection, the fact that its
main effects are beyond the reproductive lifespan of humans, has
posed an interesting puzzle for the mechanisms through which
selection is applied. Finch and Sapolsky [60,71] suggested that the
spread of e3 in human populations is due to the effect of a mother’s
late survival on the fitness of her offspring. The grand-mother
hypothesis, as it is known, is centred on the idea that the mother-
child food sharing seen among hunter-gatherers may allow post-
reproductive grandmothers to enhance their daughters’ fertility,
thus elevating their own fitness and increasing the selection for
Figure 3. Change in frequency of the three APOE alleles with each generation. The long dash line represents the e3 allele, the solid line the
e4 and the short dash line the e2. The squares, stars and triangles points represent the 95% Confidence Intervals of the e3, e4 and e2 frequencies
respectively.
doi:10.1371/journal.pone.0010022.g003
Table 2. The simulated average lifespan in years of each
variant considered in the absence of non APO E related
mortality.
Run Parameters
Mean
Lifespan
Default Default 75.69
Default 2 Default values with 30% CVD associated mortality 75.69
Diet 1 Heart Healthy and Light Eating groups decreased by
20%
74.93
Diet 2 High Fat and Empty Calorie groups decreased by
20%
75.98
Alcohol 1 Light and non-drinkers decreased by 25% 75.97
Alcohol 2 Heavy drinkers decrease by 25% 75.54
Exercise 1 Entire population moderately active (2.5h/week) 76.19
Exercise 2 Most active groups decreased by 25% 75.41
Smoking 1 Non-smokers decreased by 25% 75.57
Smoking 2 No smokers in the population 82.95
doi:10.1371/journal.pone.0010022.t002
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long postmenopausal lifespan [72,73,74]. Finch and Sapolsky
[60,71] argued that this evolutionary advantage will have caused
selection for an APOE allele that will have delayed neuropathology
and mortality even if its effects are evident later in life (for
counterarguments see [75,76]). Charlesworth [77], on the other
hand, proposed that APOE is an example of balanced polymor-
phism with the variation in the locus maintained due to the
antagonistic effects of the alleles, where increased late life risk is
offset by advantages in younger ages, in accordance with the
antagonistic pleiotropy theory of ageing. Martin [76] extended the
idea of antagonistic pleiotropy for APOE suggesting that the e4
allele could be advantageous in cases of infections with pathogens
requiring host lipids for survival. Parasites like Trypanosome brucei
not able to carry out de novo liposynthesis may depend upon host
LDL for acquisition of lipids, with the high affinity of e4 for some
lipids actually hindering their uptake by the pathogen. Our model
indicates that, although these hypotheses might work at a
secondary level, they are not strictly necessary to explain the
selection of APOE alleles. The direct effect of APOE on the mortality
or morbidity of the population is sufficient, at least in
contemporary Western populations, to produce a selection
differential between the three alleles. The simulation predicts that
the e3 and e2 alleles are driven towards fixation, a conclusion
supported by the Fullerton et al [59] observations for the mutation
at site 3937, characterising the e3 allele.
This simulation study is considering the pressure of natural
selection on a population with demographics equal, or similar, to
what is found in contemporary populations. It will be wrong to
extrapolate our results in order to interpret the early evolution of
APOE, since modern populations experience a very different
environment compared to our early ancestors. Nevertheless, our
basic conclusion that certain genetic polymorphisms, such as
APOE, exhibiting their main effect later in life can still be under the
action of natural selection, still holds. Interestingly, analysis of a
Danish cohort of individual born between 1895 and 1899, showed
that carriers of the e4 allele had increased early mortality
compared to those carrying the e2 allele as suggested by our
simulation [78]. It is currently unclear how far back our results can
Table 3. Mean change of the frequency of each allele for the variants of the model used together with the 95% CI of the standard
error of the mean in each case.
Run APO E allele
Mean change of allele
frequency per generation 95% confidence intervals for the mean
e2 0.0003352 0.0002661 0.0004043
Default e3 0.0002785 0.0001809 0.0003761
e4 20.0006137 20.0006946 20.0005327
e2 0.0000846 0.0000497 0.0001195
Default 2 e3 0.0000846 0.0000316 0.0001377
e4 20.0001692 20.0002140 20.0001244
e2 0.0000900 0.0000547 0.0001252
Diet 1 e3 0.0000899 0.0000360 0.0001438
e4 20.0001798 20.0002257 20.0001340
e2 0.0000809 0.0000480 0.0001139
Diet 2 e3 0.0000643 0.0000130 0.0001157
e4 20.0001453 20.0001905 20.0001000
e2 0.0000836 0.0000524 0.0001148
Alcohol 1 e3 0.0000818 0.0000326 0.0001309
e4 20.0001654 20.0002081 20.0001226
e2 0.0000847 0.0000500 0.0001195
Alcohol 2 e3 0.0000588 0.0000074 0.0001103
e4 20.0001436 20.0001880 20.0000991
e2 0.0000895 0.0000555 0.0001235
Exercise 1 e3 0.0000629 0.0000108 0.0001149
e4 20.0001524 20.0001959 20.0001088
e2 0.0001088 0.0000749 0.0001427
Exercise 2 e3 0.0000637 0.0000115 0.0001158
e4 20.0001725 20.0002171 20.0001279
e2 0.0001283 0.0000897 0.0001668
Smoking 1 e3 0.0000974 0.0000383 0.0001564
e4 20.0002256 20.0002766 20.0001746
e2 0.0000406 0.0000205 0.0000607
Smoking 2 e3 0.0000259 20.0000057 0.0000574
e4 20.0000665 20.0000936 20.0000393
doi:10.1371/journal.pone.0010022.t003
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be considered as valid, but given the early age (.35 years of age)
that the APOE effects on mortality can be seen in the Danish
cohort, we believe that this can extend in our recent history.
In our simulation we cannot account for any pleiotropic effects
of APOE. We described the effects of the gene on lifespan only
through its relation to elevated risk for CVD. APOE has a much
wider role than just lipid metabolism, including immunoregulation
and susceptibility to infections [60,79,80,81]. We chose not to
include these effects within the simulation since reliable quanti-
tative data concerning their impact on lifespan do not exist. APOE,
though its role in steroidogenesis, has also been shown to influence
fertility in pre-industrial populations [82], old Italians (.80 years
of age) [83] and North European males [84], with the e2 carriers
having less children. The small number of e2 subjects together
with the many cultural and socioeconomic factors affecting current
human reproduction makes it difficult to say if this effect is indeed
real and relevant in the model used. A limitation of our model was
the lack of data for the interaction between the APOE genotypes
and each of the modifiable risk factors considered, which forced us
to use a very approximate method to calculate the unknown
interactions. Further epidemiological work is required to elucidate
the precise quantitative relationship of the APOE gene with the
parameters of the model so that the predictions can be made more
accurate. While, for simplicity, we assumed that the rest of the risk
factors are independent of each other, although it has been
recognised that these tend to cluster, to some degree, in individuals
of high risk [85].
Despite some limitations, our results indicate that although the
main effect of APOE is seen after the end of the reproductive
lifespan of humans, the relatively rare events of early mortality or
morbidity are enough to produce selection against the e4 allele.
Considering these findings in the light of the evolutionary theory of
ageing and longevity, particularly as regards the ‘mutation
accumulation’ of late acting deleterious alleles, we can identify
an important perspective on this concept. Since most longevity-
associated genes, such as APOE, will cause a distribution around a
mean for the corresponding mortality, evolution will rarely, if ever,
manage to push deleterious gene action entirely beyond the reach
of selection, although as envisaged by Medawar there will be a
continual selection pressure to postpone such action to later and
later ages. The gradual postponement of the detrimental gene
effect will take place simultaneously in a wide array of mortality
associated genes. Any single mortality distribution exposed
significantly more often to the action of selection will be moved
towards older ages faster, until it reaches a balance with all the
other detrimental genotypes. This process will continue to drive
the longevity of the organism until the age-related mortality
becomes non-significant in relation to the age-independent
mortality. In this respect the evolution of longevity, although
based on selection of individual genes, is more of an evolutionarily
coordinated transfiguration of the whole genome to achieve the
maximum lifespan in the given conditions as hypothesized by
Hamilton [38].
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